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An Approach to Mechanism-based Cancer
Risk Assessment for Formaldehyde
by Rory B. Conolly and Melvin E. Andersen
The established carcinogenicity of formaldehyde in the rat and suggestive epidemiological evidence that
formaldehyde may be a human carcinogen have led to its regulation by U.S. Federal agencies as a probable
human carcinogen. These risk assessments have typically been based on tumor data in F344 rats exposed
chronically to formaldehyde by inhalation and used the inhaled concentration as a measure ofdose and the
linearized multistage model (LMS) for dose-response characterization. Low-dose risks estimated with the
LMS are thought to be conservative but are also generally acknowledged to be highly uncertain. In this
manuscript, we first consider in generic terms how use of chemical-specific data on mechanisms of target
tissuedosimetryandtheseries oftissue responsestothechemicalthatculminate in tumorformation canlead
to more accurate dose-response characterization. Aplanned mechanism-based riskassessment forformalde-
hyde is then described. This risk assessment uses data on target tissue dosimetry, size of the target cell
population intheratnasal epithelium, numberandsizeofputativepreneoplasticlesions,andtumorincidence.
These data establish parameter values for a biologically based, multistage cancer model that is then used to
predict cancerrisk at low exposure levels. Such workprovides insights into the relative roles offormaldehyde-
stimulated cell replication and procarcinogenic mutation in tumor formation. Finally, future directions are
outlined forresearch on tissue dosimetry andscaling ofthe mechanism-based formaldehyde risk model from
rats to people.
introduction
Formaldehyde is a commercially important chemical
and a common air contaminant in the workplace and the
home (1-4). Although formaldehyde is a primary irritant
(5,6) and may be a sensitizer in a subset ofthe population
(7), its potential carcinogenicity is the health effect of
greatest concern. Formaldehyde causes squamous cell
carcinoma in the nasal cavity of rats and mice exposed
chronically to relatively high concentrations (6) (Table 1).
Human epidemiological studies are equivocal as to
whether long-term formaldehyde exposure is associated
with respiratory tract cancer (8,9). When epidemiological
evidence isunequivocal andincludes sufficientinformation
onthe exposure-response relationship, human cancerrisk
assessment may be based on the epidemiological data
ratherthan onanimal studies. Benzenehasbeenregulated
inthis manner (10). Theepidemiological dataforformalde-
hyde, however, are notby themselves sufficient to support
aquantitative cancerrisk assessment (8,9). Formaldehyde
risk assessment has thus been based on data obtained
from animal experiments. The U.S. EPA published a can-
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cer risk assessment forformaldehyde in 1987 (11) and has
recently considered a revised risk assessment incorporat-
ing data on tissue dosimetry (9).
The purpose of this manuscript is to provide a critical
reviewoftheuseofthelinearizedmultistage (LMS)model
in the current approach to cancer risk assessment to
examine how this approach can be improved by including
data on the mechanisms linking exposure with carcino-
genic response and to outline how this mechanistic
approach will be used with formaldehyde. For our pur-
poses, "mechanism" refers to how an event takes place.
The events of interest are a) the disposition of toxic
chemicalsthroughoutthebodyandespeciallytothetarget
tissue(s), b) the initialbiochemical interactionbetween the
chemical and target tissue, and c) the tissue response
characterized by progressive cellular alterations leading
tofranktissuetoxicity, carcinogenicity, oranyofavariety
of end points. The interactions among physiochemical,
Table 1. Nasal cavity squamous cell carcinoma incidence in
formaldehyde-exposed rats.a
Formaldehyde concentration, ppmb Thmor prevalence
0 0/160
2.0 + 0.01 0/160
5.6 ± 0.02 2/160
14.3 ± 0.04 87/160
aFromStarrandBuck(29).Numberoftumor-bearinganimals/number
of animals considered to be at risk.
bMean + SE over 24 months.CONOLLYAND ANDERSEN
physiological, biochemical, and molecular factors provide
themechanisticbasis ofdisposition, toxicant-targettissue
interaction, and toxic effects in an animal species at
various dose levels ofachemical. Theinterplayofallthese
factors determines how a particular process takes place.
The actual mechanism-based formaldehyde risk assess-
ment is not presented.
Default Approach to Cancer Risk
Assessment
Riskassessmentis amultistepprocessinvolvinghazard
identification, dose-response assessment (including ani-
mal to human extrapolation), exposure assessment, and
riskcharacterization (12). (Thedose-responseassessment
ismoreappropriatelydefined astheexposure-response or
exposure-dose-response assessment.) Our efforts focus
on the exposure-response characterization, as this com-
ponent of the overall risk-assessment process is ripe
for significant modification by inclusion of mechanistic
data.
Inthe currentstandard approachtocancerriskassess-
ment, correlational data on the relationship ofexposure to
tumor response are obtained in arodent bioassay and are
used, alongwith aseries ofdefaultassumptions, topredict
human health risk. For example, the formaldehyde risk
assessment conducted by the EPA (11) used data on the
tumor response in F344 rats exposed chronically to 2.0,
5.6, or14.4ppmformaldehyde (Table 1). People areusually
exposed to much lower levels offormaldehyde. Prediction
of the shape of the tumor response curve expected in
people for the lower, more relevant exposure levels is thus
necessary. The EPA (11) prediction was obtained with the
LMS model, a polynomial function whose parameters are
adjusted to obtain an exposure-response curve that fits
the tumor data and predicts a nonzero response for all
nonzero exposure levels (13,14). The results are typically
presented as the upper 95% confidence bound on the risk
estimate rather than as ameanvaluefor agiven exposure
level.
Low-dose risk predictions using the LMS model are
generallythoughttobe conservative andprotective ofthe
publichealth. However, the LMS does notusemechanistic
data specific to the chemical being regulated, and one
cannot state with any certainty the degree to which the
shape ofthe curve predicted bythe LMS for the low-dose
region is a true representation ofthe real-world curve. A
LMS-based risk assessment may be overly conservative,
engendering unnecessarily stringent regulation and
correspondingly high costs for exposure control. On the
otherhand, there is also some presumably smallpossibility
that true risk is underestimated by ignoring mechanistic
data. In the following section we consider how the uncer-
tainties in low-dose extrapolation encountered with the
LMSmodel canbereducedbyexplicitconsideration ofthe
biological mechanisms that link exposure with carcino-
genic response.
Mechanism-based (Biologically
Based) Risk Assessment
No approach is currently available that allows us to
state with certainty the real-world risks associated with
exposure to any carcinogenic chemical at exposure con-
centrations other than those for which epidemiological
data exist. Nevertheless, the uncertainties surrounding
use ofthe LMS can be reduced iflow-exposure extrapola-
tionisbased onmechanistic data, i.e., onthe actualbiolog-
ical determinants ofthe carcinogenic response in animals.
Use ofmechanistic data does nothave to be an all-or-none
phenomenon. Even a partial description of the relevant
mechanism(s) is better than none at all. Any mechanism-
based model will be incomplete, inevitably omitting some
critical aspects of the overall linkage between exposure
and tumorigenic response. The short-range goal is onlyto
incorporateavailableinformationwiththeexpectationthat
the resulting risk prediction will be more accurate than a
prediction ignoring available mechanistic data. A
mechanism-basedpredictionwillbecomemore accurateas
the description of mechanism is refined, providing an
incentiveforthedesignandconductofmechanisticstudies
as asupplementto standard carcinogenicitybioassays. Of
course, in the absence of adequate mechanistic data, the
use ofdefault procedures, including reliance on the LMS,
may still be necessary.
Conolly et al. (15,16) described a generic, quantitative,
mechanism-based, exposure-response model for chemical
carcinogens. Thisproposed comprehensive model consists
ofasequence ofthree submodels thatcollectively describe
the overall process ofchemical carcinogenesis. These sub-
models are tissue dosimetry, early tissue response, and
cancer (late tissue response) (Fig. 1).
The tissue dosimetry submodel, usually based on a
physiologicallybasedpharmacokinetic (PBPK) model, is a
mechanistic model for the pharmacokinetic behavior of a
chemicaland,morespecifically,forthepredictionoftarget
tissue dosimetry. The essential features ofPBPK models
have been extensively discussed elsewhere (17-19).
The submodel for early tissue response describes, in as
much mechanistic detail as possible, the quantitative rela-
tionship between the tissue dose of the chemical and its
initial cellular effects, including DNAdamage, cytolethal-
ity, or mitogenic stimulation. Any particular carcinogen
mayexertoneormoreoftheseeffects, aswellasothersnot
specifically listed here. In general, much less work has
been done on tissue response models than on PBPKmod-
els.Attemptstodevelopcomprehensive,mechanism-based
exposure-response models highlight the lack ofprogress
in this area and can, thereby, help to focus research
resources where they are most needed.
Finally, a mechanism-based cancer submodel, the
Moolgavkar-Venzon-Knudson (MVK) model (20-22),
describes, at the cellular level, the roles of cell replication
and heritable, procarcinogenic genetic change (mutation)
inthemechanismbywhichmalignanttumors arisefrom a
population ofinitially normal cells. Reasons for use ofthe
MVKmodelinthis contexthavebeen discussed elsewhere
(15,16,23).
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FIGURE 1. Ageneric, quantitative, mechanism-based exposure-response model for chemical carcinogens. A dosimetry model (often a physiologically
basedpharmacokineticmodel)translatestheexposureexternaltotheorganismtoadoseoftheactiveformofthechemicalinthetargettissue. Next,the
mechanism linkingthepresence ofthechemical inthetissuewithearlyresponses such ascytolethality, mitogenesis, or DNAdamageis described in as
muchrelevantdetail asisavailable. Finally,therelationshipbetweentheearlyresponse andthemechanismbywhichnormalcellsbecomemalignant, as
described by the two-stage MVK model, is specified, again in as much relevant detail as is available.
As noted above, a key aspect of the overall exposure-
responsemodel as describedbyConolly et al. (15,16) is the
specification ofan earlytissue response model. This speci-
fication describes the linkage between the target tissue
dose of carcinogen and the cell replication and mutation
rateparameters ofthe MVKmodel(Fig.1). Forexample, a
cytolethal effect is described in the model as a temporary
increase inthe death rates ofcells. Resultingregenerative
cellularproliferation inthetargettissuecorresponds to an
increase in cell division rates. Unrepaired DNAdamage is
correlated with an increase in the probability of procar-
cinogenic mutation per cell division. Thus, the earlytissue
response model specifies the biochemical mechanism of
action of the carcinogen. Adequate, quantitative detail in
this component ofthe overall exposure-response model is
needed to identify behaviors that could substantially
impact the shape ofthe overall exposure-tumor response
curve. An exposure threshold for cytolethality, for exam-
ple,wouldresultinacorrespondingexposurethresholdfor
carcinogenic response as long as the chemical in question
did not act simultaneously by some other, nonthreshold
mechanism. Reitz et al. (24) have described a cancer risk
assessment for chloroform that partially implements this
generic approach.
The mechanism-based approach to cancer risk assess-
ment will not necessarily provide lower estimates of risk
relative to those obtained with the default methodology
using the LMS model. Rather, when implemented prop-
erly, these approaches will generate estimated risk num-
bersthataremorelikelytocorrespondtotheactualcancer
riskswhichare,ofcourse,determinedbythebiologyofthe
exposed organism and the chemical/biochemical interac-
tions ofthe carcinogen. Uncertainty in mechanism-based
risk assessment is a consequence of measurement error,
interindividual variation, and misspecification of mecha-
nism (model). Each ofthese sources ofuncertainty canbe
reduced through focused research and subsequent model
refinement. A mechanism-based approach to risk assess-
ment thus replaces the nebulous uncertainty associated
with the defaultmethodology (25) with much more clearly
defined sources of uncertainty that can be reduced by
relevant experiments.
Formaldehyde research has progressed to the point
where data describing the biological mechanism linking
formaldehyde exposure with tumor formation data are
available (26-28). Inthefollowing sectionwe consider how
the default exposure-response assessment for formalde-
hyde can be improved by inclusion ofthese data.
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Mechanism-based Risk Assessment
for Formaldehyde
Tissue Dosimetry
Ongoing work at the Chemical Industry Institute of
Toxicology (CIIT) is adapting the generic, mechanism-
based exposure-dose-response model described above to
cancerrisk assessment for formaldehyde. The initial step
in this direction was use oftarget tissue dosimetry data,
rather than exposure concentration, for the exposure-
dose-response characterization step of the overall risk
assessment process. Even without specific consideration
of mechanisms of tissue response, this innovation mark-
edly affected the predictions of low-dose risk (9,29,30).
Formaldehyde-derived DNA-protein cross-links (DPX) in
thenasalrespiratoryepitheliumoftheF344ratwereused
as a measure of delivered dose (29,30). Although these
DPXmaybecausallylinkedtobothformaldehyde-induced
mutation and cytolethality, no such mechanistic role was
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assumed in using DPX as a target tissue dosimeter. The
relationship between formaldehyde exposure concentra-
tion and DPX formation is highly nonlinear, with the rate
of DPX formation increasing disproportionately as for-
maldehyde exposure levels increase (Fig. 2). The non-
linearity exists because some oftheinhaled formaldehyde
absorbed in the target region never exerts a toxic effect
due to nonlinear clearance processes. For example,
mucociliaryfunction in the rat nose is inhibited by15 ppm
formaldehyde, but6ppmhasmuch lesseffect, and 0.2ppm
has none at all (31).
TheDPXdatawereusedinplaceofexposureconcentra-
tionasinputtothe LMSmodelandlessriskwaspredicted
for the lower exposure levels (Table 2). The potential
impactoftargettissue DPX onformaldehyde risk assess-
ment has also recently been considered by the U.S. EPA
(9). Theirproposed revision ofthe 1987 formaldehyde risk
assessment (11) predicts a lower risk at low levels of
exposurewhen DPX data are used as inputto the LMS in
place ofinhaled concentration offormaldehyde.
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[CH2O] (ppm)
FIGURE 2. Averageconcentration ofDNA-protein cross-links formed per unittime in the turbinates and lateralwall/septum ofF344 rats and rhesus
monkeys versus the airborne formaldehyde concentration. All animals were exposed for 6 hr to formaldehyde. Dashed lines are 95% confidence limits
about the mean for each species. Modified from Casanova et al. (34).
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lable 2. Upper 95% confidence-bound risk estimates per million,
as derived with the three-stage carcinogenesis model.a
Formaldehyde Dose measure/speciesb
concentration, ppm Air/rat CVB/rat CVB/monkey
1.0 1800 1200 140
0.5 810 420 41
0.1 160 74 8
aModified from Starr (30).
bCVB: 14C-formaldehyde covalent binding data, a measure of DNA-
protein cross-links.
Iarget Tissue Response
Inadditiontotargettissuedosimetrydata,alargebody
of tissue response data has recently been obtained in a
long-term pathogenesis study at CIIT (23,26) in which
tissue responses were evaluated at several time points
during chronic formaldehyde exposure at multiple con-
centrations. The essential features ofthis studywere a) a
largenumberofexposurelevels (0,2,5,10,and15ppm) b)2
years ofinhalation exposure with intermediate sacrifices
at1.5, 3, 6,12, and 18 months, and c) collection ofquantita-
tive data on a large number of end points, including
numbers of putative preneoplastic lesions and malignant
tumors, numbers of cells in normal target tissue, pre-
neoplastic lesions and tumors, and labeling indices forthe
estimation of cell division rates in normal tissue, pre-
neoplastic lesions, and tumors. As already described (23),
thisdatasetcanbeusedtoestimatealltheparametersofa
two-stage MVKmodel. The planned approach to estimat-
ing these parameter values and using the MVK model to
develop risk estimates for formaldehyde has been
describedindetail(23)andisnowreviewedbriefly(Fig.3).
First, the MVKmodel is configured for control animals
(basalmodel). Estimatesoftargetcellpopulationsizefrom
the CIIT pathogenesis study, rates of cell division in
control rats, and data or upper-bound estimates of num-
bers of preneoplastic lesions and malignant tumors are
used to provide parameter values. These data are also
used to estimate the baseline probabilities of procar-
cinogenicmutationpercelldivision (23) (Fig. 3). Thebasal
model is modified by adding cell proliferation data from
formaldehyde-exposed animals (replication model; Fig. 3).
Finally, the replication model is modified by including a
proportionality constant between DPX and an increase
over the baseline value in the probability of procar-
cinogenic mutation per cell division (mutation model; Fig.
3). The value of the increase in mutation probability is
estimated by fitting the model to actual tumor data (23).
Forthebasal,replication,andmutationMVKmodels,all
parameters are based on laboratory data. This family of
MVK models represents alternative, biologically based
hypotheses about the mechanism of formaldehyde car-
cinogenesis in the F344 rat. The abilities ofthese alterna-
tive hypotheses, encoded as simulation models, to predict
the actual tumor data are compared statistically (Table 3)
(32).
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FIGURE 3. The generic exposure-dose-response model in Figure 1 modified for the nasal tumorigenicity of formaldehyde. Inhalation exposure to
formaldehyde is correlated with DPX in the respiratory epithelium. DPX are used as a measure oftissue dose ofreactive formaldehyde and have no
othermechanistic significance isthis description. Theearly consequences ofthetissuedose, cytolethality, andensuingcellreplication, orDNAdamage
andmutation, arecorrelatedwithDPX.Cellreplicationdata areuseddirectlyintheMVKmodel.Aproportionalityconstantisdefinedbetween DPXand
increases in the probabilities ofmutation per cell division. The relative roles ofcell replication and mutations in formaldehyde tumorigenesis are then
evaluated as described in the text.
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Table 3. Possible fits offormaldehyde
cancer risk models to tumor data.
Quality offita
Mutation and
Baseline Cell cell
Case no. model replication replication
1 10 10 10
2 1 10 10
3 1 1 10
4 1 5 10
aUnits are arbitrary. Hypothetical bestfitin each caseis given avalue
of10.
a) A significantly better simulation of the tumor data
withthemutation modelthanwith eitherthereplication or
basal models would indicate that a mutagenic effect of
formaldehyde, in combinationwith stimulated cell replica-
tion, plays themajorroleintumorigenesis. Thehypothesis
that formaldehyde is producing tumors simply by induc-
tion ofmutation appears untenable in the face ofthe large
increases in replication rates in affected tissues.
b) Equally good simulations of the tumor data by the
mutation and replication models would suggest that
formaldehyde-stimulated cell replication plays the major
role in tumorigenesis as the fit to the tumor datais not, in
this case, improved by describing a direct mutagenic
effect.
c) Finally, if none of the models provide reasonable
simulations ofthetumordata,thehypothesis thatthetwo-
stage MVK description is appropriate for formaldehyde
carcinogenesiswillbereevaluated. Thislatterresultwould
suggest that another model, perhaps with more than two
stages, would be more appropriate. Development of more
complex MVK-type models will then be pursued, while
maintaining the approach of estimating as many of the
parameter values as possible directly from data.
Animal to Human Scale-Up
Mechanism-based modeling of target tissue dosimetry
and response, as described above, provides a description
of the complete inhalation exposure-nasal tumor-
response curve for the F344 rat. Human risk assessment
requires consideration of how this description should be
adjusted (scaled) to account for differences between rats
and people. This scaling process includes interspecies
adjustments for both tissue dosimetry and tissue
response.
Scaling Tissue Dosimetry
Casanova et al. (33,34) described a pharmacokinetic
model for DPX formation due to formaldehyde exposure
thataccuratelyreproduces measured DPXconcentrations
inboth F344rats andrhesusmonkeys. Thismodelhas also
been used to predict expected human DPX. A relatively
straightforward scaling approach for tissue dosimetry is
to use the model developed by Casanova and colleagues to
predict human DPX for exposure scenarios of interest.
Quantitative relationships established for the F344 rat
between DPX and stimulation ofcell replication and DPX
and an increase in the probability of mutation per cell
division (see above) arethenusedto constructaformalde-
hyde risk model for humans. This human model would
reflect scaling of target tissue dosimetry (DPX), but the
use of the tissue response description developed for the
rat.
Scaling Tissue Response
In the context of the present approach, interspecies
scaling oftargettissue response to formaldehyde reduces
to scaling the parameters in the MVKmodel from rats to
people (compare Figs. 1 and 3). People are much larger
than rats and live many years longer. Other things being
equal, people have more cells at risk for a longer time.
Because control tumor rates are presumably similar in
rats and humans, significant adjustments in the MVK
description of cell replication rates and probabilities of
mutation per cell division must be made to account for
these interspecies differences. This is an area where we
are badly in need of new data. Given the current lack of
relevant data, it seems appropriate for the time being to
simplyuse the tissue-response description defined forthe
rat as the basis for the human risk model.
Remaining Questions and Future
Directions
The approach described here for developing a
mechanism-based risk assessment model for formalde-
hyde carcinogenesis assumes thatthe ratis agood surro-
gate for the human. Epidemiological studies suggest that
ifformaldehyde causes anyhuman cancers at all, they are
most probably of the nasopharynx and lung (8,9). F344
rats exposed to formaldehyde have onlydeveloped tumors
ofthenasalrespiratoryepithelium (6).Thus,theremaybe
significant differences in target site for formaldehyde
carcinogenesis betweenrats andpeople. Herewe consider
how this issue can be addressed by extension of the
mechanism-based risk model for formaldehyde.
With respect to tissue dosimetry and rat to human
extrapolation, we are interested in how the regional dos-
imetrypattern in the entire rat respiratory tract, notjust
in the nose, compares to that for the human. Research
underway at CIIT, and other laboratories, on computer
simulation of airflow in the rat and human respiratory
tracts has the potential, when coupled with physiochemi-
cal and mass fluxequations, toprovide accurate, quantita-
tive predictions ofregional deposition ofinhaled gases in
the nose,nasopharynx, andlung(35-37).Assumingequiv-
alent responsiveness ofthe cells liningthe airways in rats
and people, knowledge of regional dosimetry, combined
with the known regional tumor response in the rat, will
permit prediction of the sites in the human respiratory
tract most at risk for developing irritation and tumors in
response toformaldehyde exposure. This approach allows
prediction of the human exposure scenarios required to
cause a measurable tumor incidence. Development of the
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risk model to this point provides the opportunity for
comparison of model predictions with epidemiological
data.
These considerations of how simulation of regional
tissue dosimetry may allow more sophisticated scaling of
the mechanism-based formaldehyde risk model have all
assumed equivalent tissue responsiveness. That is, we
have assumed that the target tissue dose-carcinogenic
response relationship for cells lining the respiratory tract
is the same for rats and humans. This is almost certainly
an oversimplification, but, for the present, there are no
datawithwhichtotesttheassumption. Itisworthremem-
bering that risk assessment, for formaldehyde or for any
otherchemical, is anevolvingprocess. Norisk assessment
is likely, in the foreseeable future, to be both absolutely
accurate and precise for every member of the hetero-
geneous human population. This is true even if the
approach outlined here is modified to obtain risk estimate
ranges,ratherthanpointestimates,byusingdistributions
of risk model parameter values to describe variability
between people. Risk assessments will continue to evolve
as ourunderstanding ofthe physiological andbiochemical
mechanisms of tissue dosimetry and tissue response
improves. Our approach for formaldehyde involves
descriptions ofdosimetryand response atthe cellular and
tissue levels. As we learn more, it should be possible to
refine this approach also by describing the relevant car-
cinogenic mechanisms at the molecular level.
The mechanism-based approach described here is not
specific to formaldehyde. The exposure-tissue dose-early
tissue response-tumor response paradigm (Fig. 1) can be
used as a startingpointformechanism-based assessment
ofcarcinogenic riskfor anychemical. Itprovides aframe-
workforincorporation ofmechanistic dataasitis obtained
notjustwhen the mechanism has been exhaustively stud-
ied. The approach thus rewards mechanistic research
designed to support human health risk assessment and
uses the most current scientific understanding in protect-
ingthehealthofthepublicfrompotentiallyadverseeffects
oftoxic and carcinogenic chemicals.
The authors acknowledge the many helpful discussions with CIIT
colleagues, which helped shape the approach described in this work.
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